Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly […]
Erythropoietin, uncertainty principle and cancer related anaemia.
Interesting analysis -additonal evidence supporting what has now become the standard practice in the oncology community. – Patricia Ford
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales.
This helpful article offers increased understanding and ability to utilize the functional assessment of cancer therapy (FACT) scale. – Patricia Ford
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response to epoetin is an early […]
Recombinant human erythropoietin in pediatric oncology: a review.
Important to attempt review, but too much variability in studies to form meaningful conclusion. – Patricia Ford